Table 5.
Diagnostic uveitis classification for MdVL, MVL, SVL for those eyes that had both initial and final BCVA available (n=458; 604 eyes)
| Visual loss (number of eyes [ne]) | Diagnosis | Number of eyes* (%) |
|---|---|---|
| MdVL (ne=444) | Trauma | 48 (10.8) |
| Sarcoidosis | 34 (7.7) | |
| AU-HLAB27 | 34 (7.7) | |
| MVL (ne=69) | AU-undifferentiated | 20 (29.0) |
| Sarcoidosis | 10 (14.5) | |
| Postprocedural | 6 (8.7) | |
| SVL (ne=91) | Postprocedural | 16 (17.6) |
| AU-undifferentiated | 12 (13.2) | |
| Trauma | 7 (7.7) | |
| Sarcoidosis | 7 (7.7) | |
| Panuveitis-undifferentiated | 7 (7.7) |
Note:
*
Percentages are for each group of disease severity and not for the entire study population.
Abbreviations: AU, anterior uveitis; BCVA, best-corrected visual acuity; HLAB27, human leucocyte antigen B27; MdVL, mild visual loss; MVL, moderate visual loss; SVL, severe visual loss.